KR100518266B1 - Composition comprising Bacillus polyfermenticus SCD (KCCM 10104) for usage as cholesterol-lowering agent - Google Patents
Composition comprising Bacillus polyfermenticus SCD (KCCM 10104) for usage as cholesterol-lowering agent Download PDFInfo
- Publication number
- KR100518266B1 KR100518266B1 KR10-2002-0073386A KR20020073386A KR100518266B1 KR 100518266 B1 KR100518266 B1 KR 100518266B1 KR 20020073386 A KR20020073386 A KR 20020073386A KR 100518266 B1 KR100518266 B1 KR 100518266B1
- Authority
- KR
- South Korea
- Prior art keywords
- cholesterol
- kccm
- scd
- bacillus
- bacteria
- Prior art date
Links
- 241001226430 Bacillus polyfermenticus Species 0.000 title claims abstract description 36
- 229940104704 bacillus polyfermenticus Drugs 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 239000003529 anticholesteremic agent Substances 0.000 title 1
- 229940127226 anticholesterol agent Drugs 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 85
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 39
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 abstract description 13
- 235000013305 food Nutrition 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 description 27
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 239000006041 probiotic Substances 0.000 description 15
- 235000018291 probiotics Nutrition 0.000 description 15
- 230000000529 probiotic effect Effects 0.000 description 12
- 241000193830 Bacillus <bacterium> Species 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 239000003613 bile acid Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IRHVLQMEQPABHG-ZLYSWTFPSA-N (3r,4r,5r,6r,7r,8r,9s,10r,13r,14r,17r)-3,4,6,7-tetrahydroxy-17-[(1s)-1-[(2s,4s)-6-hydroxy-4-propan-2-yloxan-2-yl]ethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-15-one Chemical compound C1[C@H](C(C)C)CC(O)O[C@@H]1[C@@H](C)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](O)[C@H](O)[C@@H]4[C@@H](O)[C@H](O)[C@H]3[C@H]2C(=O)C1 IRHVLQMEQPABHG-ZLYSWTFPSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 244000066764 Ailanthus triphysa Species 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940066544 lactobacillus sporogenes Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
Abstract
본 발명은 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) SCD 균주(KCCM 10104)를 유효성분으로 함유하는 콜레스테롤 저하용 조성물에 관한 것으로 콜레스테롤을 저하시키는 효과가 있으므로 식품, 의약품 및 사료 등의 용도로 사용될 수 있는 뛰어난 효과가 있다.The present invention relates to a composition for lowering cholesterol containing Bacillus polyfermenticus SCD strain (KCCM 10104) as an active ingredient, and thus can be used for food, medicine and feed, etc. Excellent effect.
Description
본 발명은 생균을 이용한 콜레스테롤 저하용 조성물에 관한 것으로 더욱 상세하게는, 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) SCD 균주(KCCM 10104)를 유효성분으로 함유하는 콜레스테롤 저하용 조성물에 관한 것이다.The present invention relates to a composition for lowering cholesterol using live bacteria, and more particularly, to a composition for lowering cholesterol containing Bacillus polyfermenticus SCD strain (KCCM 10104) as an active ingredient.
식생활이 서구화되고 외식의 기회가 잦아짐에 따라 지방 함량이 많고 식이섬유 함량은 적은 가공 식품의 섭취가 증가하게 되었는데 이로 말미암아 동물성 지방의 과다한 섭취로 인한 고 콜레스테롤 혈증이라는 성인성 질환이 많이 유발되었다(Kang, H.J. and Song, Y.S. (1997) Dietary fiber and cholesterol metabolism J. Korean Soc. Food Sci Nutr. 26, 358-369).As the diet has become more westernized and the chances of eating out have increased, the consumption of processed foods with high fat content and low dietary fiber content has led to an increase in adult diseases such as hypercholesterolemia caused by excessive intake of animal fat. Kang, HJ and Song, YS (1997) Dietary fiber and cholesterol metabolism J. Korean Soc.Food Sci Nutr . 26, 358-369).
한편, 유산균 및 발효유 제품의 섭취가 콜레스테롤 수준을 저하시킬 수 있는가에 대한 연구가 있는데, 인공 영양아의 장내균총과 혈청 콜레스테롤 함량과의 관계를 조사한 연구에 의하면 혈청 콜레스테롤 함량이 낮을 때 장내 유산균이 최우세 한 것으로 알려져 있다. 따라서, 장내세균 중의 유산균총이 인체의 콜레스테롤 대사에 중요한 역할을 한다는 것을 알 수 있다.On the other hand, there is a study on whether lactic acid bacteria and fermented milk products can lower cholesterol levels. It is known to be one. Therefore, it can be seen that the lactic acid bacteria flora in the intestinal bacteria plays an important role in cholesterol metabolism of the human body.
유산균은 일찍이 메치니코프로부터 많은 연구자들이 이를 이용한 유산균 체내에서 정장작용, 장내 병원성 세균의 발육저해, 비타민의 합성, 혈청 콜레스텔롤의 저하, 항암효과 등의 건강효과가 있음을 연구하여 발표하였다. 이런 유산균은 오래 전부터 우리들의 식생활과 밀접한 관계를 유지해왔으며, 최근에는 프로바이오틱 생균제로서 더 많이 이용되고 있다(Lin, M.Y. and Yen, C.L. (1999) Antioxidative ability of lactic acid bacteria. J. Agric. Food Chem. 47, 1460-1466). 그러한 프로바이오틱 생균제로서는 락토바실러스(Lactobacillus)속, 스트렙토코쿠스(Streptococcus)속, 비피도박테리움(Bifidobacterium)속, 엔테로코쿠스(Enterococcus)속, 클로스트리디움 부티리쿰(Clostridium butyricum), 락토바실러스 스포로제네스(Lactobacillus sporogenes), 그리고 바실러스 서브틸리스(Bacillus subtilis) 등이 있다.Lactobacillus was first published by Mechinnikov and many researchers have reported that it has health effects such as intestinal action, intestinal pathogenic bacteria development, vitamin synthesis, serum cholesterol reduction and anticancer effects. Lactic acid bacteria have been closely related to our diet for a long time, and have been used more recently as probiotic probiotics (Lin, MY and Yen, CL (1999) Antioxidative ability of lactic acid bacteria.J. Agric. Chem. 47, 1460-1466). Examples of such a probiotic probiotic Lactobacillus bacteria (Lactobacillus), A streptococcus (Streptococcus) genus Bifidobacterium (Bifidobacterium), A Enterobacter nose kusu (Enterococcus) genus Clostridium butyric rikum (Clostridium butyricum), jeneseu (Lactobacillus sporogenes), and Bacillus subtilis (Bacillus subtilis) with Lactobacillus Spokane Etc.
그러나, 최근 들어 바실러스속 프로바이오틱 생균에 대한 산업적인 유용성이 증대되고 있으며(Park, H.S., Lee, S.H. and Uhm, T.B. (1998) Selection of microorganisms for probiotics and their characterization. J. Food Sci. Nutr. 3, 433-440; Green, D.H., Wakeley, P.R., Page, A., Barnes, A., Baccigalupi, L., Ricca, E. and Cutting, S.M. (1999) Characterization of two Bacillus probiotics. Appl. Environ. Microbiol. 65, 4288-4291; Hoa, N.T., Baccigalupi, L., Huxham, A., Smertenko, A., Van, P.H., Ammendola, S., Ricca, E. and Cutting, S.M. (2000) Characterization of Bacillus species used for oral bacteriotherapy and bacterioprophylaxis of gastrointestinal disorders. Appl. Environ. Microbiol. 66, 5241-5247), 그 중에서도 비스루트균이라 불리는 바실러스 폴리퍼멘티쿠스(B. polyfermentcius) SCD (KCCM 10104)는 식품용 프로바이오틱 생균제로 주목받고 있다.However, in recent years, industrial usefulness for probiotic bacteria of the genus Bacillus has increased (Park, HS, Lee, SH and Uhm, TB (1998) Selection of microorganisms for probiotics and their characterization. J. Food Sci. Nutr . 3, 433-440; Green, DH, Wakeley, PR, Page, A., Barnes, A., Baccigalupi, L., Ricca, E. and Cutting, SM (1999) Characterization of two Bacillus probiotics.Appl.Environ . Microbiol. 65, 4288-4291; Hoa, NT, Baccigalupi, L., Huxham, A., Smertenko, A., Van, PH, Ammendola, S., Ricca, E. and Cutting, SM (2000) Characterization of Bacillus species used for oral bacteriotherapy and bacterioprophylaxis of gastrointestinal disorders. Appl. Environ. Microbiol. 66, 5241-5247), Bacillus poly flops mentee kusu (B. polyfermentcius) SCD (KCCM 10104 ) known as bis root bacteria among them is Pro Food It is attracting attention as a biotic probiotic.
바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104)는 20여종의 효소를 분비하여 영양소를 재활용하게 하며, 비타민 B1, B2, K를 합성하여 영양을 보급시킨다. 또한 인체의 3대 영양소인 탄수화물, 단백질, 지방 및 섬유소를 소화·흡수시키며, 병원성균들인 티프스균, 파라티프스균, 적리균, 콜레라균 등을 용균시켜 증식을 억제하는 기능을 가지고 있다. 특히, 시판중인 유산균제제나 비피더스균제제 등은 장까지 도달하기 위해서는 위산이나 여러 효소들 때문에 특별한 코팅이나 캡슐 제품 등을 생각해야 되지만, 이 비스루트균은 아포를 형성하기 때문에 장에 도달할 때까지 활성을 거의 잃지 않아 장질환의 치료에 탁월한 효과를 보이고 있다(백현동, 정민용, 정황영, 김원석, 김기태. (2002) 식품용 프로바이오틱 비스루트균의 주요 생균제 특성. 한국식품과학회지 34, 73-78). B. polyfermenticus SCD (KCCM 10104) secretes 20 kinds of enzymes to recycle nutrients, and synthesizes vitamins B 1 , B 2 , and K to spread nutrition. In addition, it digests and absorbs the three major nutrients of the body, carbohydrates, proteins, fats and fibres, and has the function of inhibiting proliferation by lysing pathogenic bacteria such as typhoid bacteria, paratyphoid bacteria, erythrocytes and cholera bacteria. In particular, commercially available lactic acid bacteria and bifidus bacteria should be considered special coating or capsule products due to gastric acid and various enzymes in order to reach the intestines, but because these bacteria form apo, until they reach the intestines hardly losing the activity has shown an excellent effect in the treatment of bowel diseases (Baekhyeon-dong, jeongminyong, jeonghwangyoung, gimwonseok, Kim, Ki - Tae (2002). the main characteristic of probiotic foods probiotic bacteria for service routes. Journal of the Korea Food 34, 73- 78).
그러나, 종래에 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104)에 콜레스테롤 저하능이 있다는 보고는 아직까지 없다.However, there are no reports of cholesterol lowering ability in Bacillus polyfermenticus SCD (KCCM 10104).
이에 본 발명은 현재 국내에서 산업적으로 각광받고 있는 프로바이오틱 생균제인 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104)로부터 콜레스테롤 저하 효과를 신규로 검증하고, 이를 바탕으로 콜레스테롤 저하용 조성물을 제공하는데 그 목적이 있다.In this regard, the present invention newly validates the cholesterol lowering effect from B. polyfermenticus SCD (KCCM 10104), a probiotic probiotic that is currently attracting industrial attention in Korea, and based on this, a composition for lowering cholesterol The purpose is to provide.
상기 목적을 달성하기 위하여 본 발명은 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) SCD 균주(KCCM 10104)를 유효성분으로 함유하는 콜레스테롤 저하용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for lowering cholesterol containing Bacillus polyfermenticus SCD strain (KCCM 10104) as an active ingredient.
이하, 본 발명의 구성에 대해 더욱 상세히 설명한다. Hereinafter, the configuration of the present invention will be described in more detail.
최근 식품산업은 소득 수준의 향상과 식생활 방식의 변화로 여러 형태의 건강식품에 대한 수요가 증가하고 있는 추세이며, 이에 따라 인체에 무해하며 건강 증진 기능이 있는 식품 소재를 찾기 위한 많은 연구가 진행되고 있는 실정이다. 따라서 본 발명은 현재 의약용과 식품용으로 각광 받고 있는 프로바이오틱 생균제인 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104) (소위, '비스루트균' 또는 '비스판균')의 콜레스테롤 저하 효과를 입증한다.Recently, the food industry is increasing the demand for health foods of various types due to the improvement of income level and the change of dietary lifestyle. There is a situation. Therefore, the present invention is a cholesterol of the probiotic probiotic B. polyfermenticus SCD (KCCM 10104) (so-called ' Bisroot bacterium' or ' Bispan bacterium'), which is currently in the spotlight for medical and food use. Demonstrate a lowering effect.
시험관 내(In vitro)에서 콜레스테롤 저하에 대한 실험은 효소적(BCS total cholesterol kit, Korea)방법으로 실시한다. In vitro experiments on cholesterol lowering are carried out by enzymatic method (BCS total cholesterol kit, Korea).
콜레스테롤이 저하효과는 호기적으로 배양했을 때, 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104)의 증식과 함께, 배양액 속의 콜레스테롤의 양이 시간이 경과함에 따라 감소된다.The lowering effect of cholesterol decreases over time with the growth of B. polyfermenticus SCD (KCCM 10104) when cultured aerobicly .
또한, 콜레스테롤의 저하에 대한 담즙산의 영향을 알아보기 위한 실험으로 0.0%, 0.3% 'oxgall'을 첨가하여 실시하면, 'oxgall' 0.0 %(v/v) 첨가구에서 초기 콜레스테롤 양보다 67.08 % , 0.3 %(v/v) 첨가구에서 초기 콜레스테롤 양보다 64.14 %의 감소율이 각각 나타난다. In addition, experiments to determine the effect of bile acids on the lowering of cholesterol, when 0.0%, 0.3% 'oxgall' was added, the 'oxgall' 0.0% (v / v) added 67.08%, The 0.3% (v / v) addition resulted in a 64.14% reduction in initial cholesterol.
결과적으로, 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) SCD (KCCM 10104)의 콜레스테롤의 저하효과가 확인되며 향후 의약품, 기능성 식품 및 사료분야에서 콜레스테롤 저하를 위한 기능성 소재로서 활용이 가능할 것이다.As a result, the lowering effect of cholesterol of Bacillus polyfermenticus SCD (KCCM 10104) is confirmed, and may be used as a functional material for lowering cholesterol in medicine, functional food and feed.
이하, 본 발명의 구성을 하기 실험 및 실시예를 들어 더욱 상세히 설명하지만 본 발명의 권리범위가 하기 실험 및 실시예에만 한정되는 것은 아니다. Hereinafter, the configuration of the present invention will be described in more detail with reference to the following experiments and examples, but the scope of the present invention is not limited only to the following experiments and examples.
하기 실험예에서 사용한 알파-토코페롤(α-tocopherol; α-toc)은 'Sigma'사 로부터 구입하여 사용하였다. 그리고 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) SCD (KCCM 10104)는 (주)바이넥스에서 분양받은 후 3∼4회에 걸친 계대배양으로 활성화하였으며 글라이세롤 스톡(glycerol stock)법으로 -70℃에서 보존하였고, 워킹 컬쳐(working culture)는 한달에 1회씩 계대배양을 하여 사용하였다(전경동, 이광호, 김원석, 백현동. (2000) 의약용 프로바이오틱 비스판균의 미생물학적 동정. 산업미생물학회지 28, 124-127). 바실러스 폴리퍼멘티쿠스(B.polyfermenticus) SCD (KCCM 10104)의 배양 배지는 TSB 배지(Difco Laboratories, Detroit, USA)를 사용하였다.Alpha-tocopherol (α-tocopherol; α-toc) used in the following experimental example was purchased from 'Sigma'. Bacillus polyfermenticus SCD (KCCM 10104) was activated by three to four passages after pre-incubation at Vinex , and stored at -70 ° C by glycerol stock. Working cultures were used for subcultures once a month (Jun Kyung-dong, Lee Kwang-ho, Kim Won-seok, and Baek Hyun-dong. (2000) Microbiological Identification of Medical Probiotic Bispan bacteria. Journal of the Industrial Microbiology 28, 124-127). TSB medium (Difco Laboratories, Detroit, USA) was used as a culture medium of B. polyfermenticus SCD (KCCM 10104).
콜레스테롤 잔존량은 효소적 방법(BCS Total cholesterol kit, Korea)으로 실시하였고, 균수는 표준 평판 계수법으로 37℃에서 실시하였다. Cholesterol remaining was carried out by enzymatic method (BCS Total cholesterol kit, Korea), the number of bacteria was carried out at 37 ℃ by standard plate counting method.
실험예 1: 바실러스 폴리퍼멘티쿠스(Experimental Example 1: Bacillus polyfermentus ( Bacillus polyfermenticusBacillus polyfermenticus ) SCD (KCCM 10104)의 콜레스테롤 저하능 조사 Investigation of Cholesterol-lowering Potential of SCD (KCCM 10104)
콜레스테롤 저하 효과에 대한 실험으로 우선 0.1%(v/v) 콜레스테롤이 첨가된 TSB 브로쓰(broth) 60 mL에 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) SCD (KCCM 10104)를 접종하여 0, 2, 4, 6, 12, 24 시간 간격으로 배지안의 남은 콜레스테롤의 양과 이때의 균수를 측정하였다.As an experiment on the cholesterol lowering effect, first, 60 mL of TSB broth to which 0.1% (v / v) cholesterol was added was inoculated with Bacillus polyfermenticus SCD (KCCM 10104). The amount of cholesterol remaining in the medium and the number of bacteria were measured at intervals of 6, 12, and 24 hours.
호기적으로 균을 배양시켰을 때 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104)의 증식이 이루어졌으며, 배양액 속의 콜레스테롤의 양이 시간이 경과함에 따라 감소되는 결과를 나타내었다(도 1). 그러나, 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104)를 접종하지 않은 대조구에서는 콜레스테롤의 감소가 나타나지 않았다.The growth of Bacillus polyfermenticus SCD (KCCM 10104) was achieved when the bacteria were cultured aerobicly , and the amount of cholesterol in the culture medium was decreased over time (Fig. 1). . However, there was no decrease in cholesterol in the control group not inoculated with B. polyfermenticus SCD (KCCM 10104).
따라서, 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104)에 콜레스테롤을 감소시키는 능력이 있음을 알 수 있었다. 또한 콜레스테롤 저하하는 다른 균주들(실험조건 및 방법은 상기의 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104)와 동일)과 비교를 표 1에 나타내었는데 이들과 비교 실험에서도 높은 활성을 보여주었다.Thus, it was found that B. polyfermenticus SCD (KCCM 10104) has the ability to reduce cholesterol. In addition, compared to other strains that lower cholesterol (experimental conditions and methods are the same as the above B. polyfermenticus SCD (KCCM 10104)) is shown in Table 1 and showed a high activity in comparison experiments with these gave.
실험예 2: 바실러스 폴리퍼멘티쿠스(Experimental Example 2: Bacillus polyfermentus ( Bacillus polyfermenticusBacillus polyfermenticus ) SCD (KCCM 10104)의 콜레스테롤 저하에 대한 담즙산의 영항 조사Investigation of the Effect of Bile Acids on Cholesterol Lowering in SCD (KCCM 10104)
콜레스테롤 저하에 담즙산의 영향에 대한 실험으로 0.0%(v/v), 0.3%(v/v) 'oxgall(Difico laboratory, USA)'이 첨가된 TSB 배지에 0.1%(v/v) 콜레스테롤(Sigma)을 첨가하여 60 mL을 제조하고 37℃에서 24 시간 호기적으로 배양하였다. 0.1% (v / v) cholesterol (Sigma) in TSB medium supplemented with 0.0% (v / v) and 0.3% (v / v) 'oxgall (Difico laboratory, USA)' ) Was added to prepare 60 mL and incubated at 37 ° C. for 24 hours.
배양 후 배양액 10 mL을 4,000×g로 4℃에서 10분간 원심분리하여 상등액과 균체를 분리하였다. 상등액이 제거된 균체에 동량의 포스페이트 버퍼(phosphate buffer) (NaH2PO4/Na2HPO4: 0.1 M, pH 7) 용액 10 mL을 넣어 현탁시켰다. 다시 이 현탁액을 4,000×g로 4℃에서 10분간 원심분리하여 균체와 세척액(washing buffer)을 얻었다. 각각 얻어진 균체, 배양상등액, 세척액에서 콜레스테롤을 측정하였다. 콜레스테롤 측정은 효소적법 (BCS total cholesterol kit, Korea) 법으로 실시하였다. After incubation, 10 mL of the culture solution was centrifuged at 4,000 × g at 4 ° C. for 10 minutes to separate the supernatant and the cells. 10 mL of a solution of the same amount of phosphate buffer (NaH 2 PO 4 / Na 2 HPO 4 : 0.1 M, pH 7) was suspended in the supernatant-free cells. The suspension was further centrifuged at 4,000 × g at 4 ° C. for 10 minutes to obtain cells and washing buffer. Cholesterol was measured in each of the obtained cells, culture supernatant, and wash solution. Cholesterol was measured by enzymatic method (BCS total cholesterol kit, Korea).
바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104)의 콜레스테롤 저하능에 있어, 담즙산의 영향을 알아보기 위한 실험으로 0.0%(v/v), 0.3%(v/v) 'oxgall'을 첨가하여 실시한 결과를 표 2에 나타내었다. B. polyfermenticus SCD (KCCM 10104) in the hypocholesterolemic activity, the addition of 0.0% (v / v), 0.3% (v / v) 'oxgall' in the experiment to determine the effect of bile acids Table 2 shows the results obtained.
초기 콜레스테롤 양보다 'oxgall' 0.0%(v/v) 첨가구에서 67.08 % , 0.3% 첨가구에서 64.14 %의 감소율을 각각 나타났다. 이와 비슷한 실험에서 유산균이 콜레스테롤을 감소시킬 때 담즙산 농도에 따라 감소율 달라져 담즙산에 영향을 받는다는 보고가 있는 반면 존재하는 담즙산에 상관없이 유산균은 콜레스테롤을 저하시킨다는 보고도 있다(Tahiri, K., Grill, J.P., Schneider, F. (1996) Bifidobacteria strain behavior toward cholesterol: coprecipitation with bile salt and assimilation. Curr. Microbiol. 33, 187-193). 그러나 본 발명에서는 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104)는 'oxgall' 농도 0.0%(v/v) 및 0.3%(v/v)에 상관없이 직접 콜레스테롤의 잔류 함량을 저하시켜 담즙산의 영향을 받지 않은 것으로 알 수 있었다.The reduction rate of 67.08% in the 'oxgall' 0.0% (v / v) group and 64.14% in the 0.3% group was lower than the initial cholesterol level. Similar experiments have reported that when lactic acid bacteria decrease cholesterol, the rate of decrease depends on the concentration of bile acids, which affects bile acids. However, lactic acid bacteria reduce cholesterol regardless of bile acids present (Tahiri, K., Grill, JP). , Schneider, F. (1996) Bifidobacteria strain behavior toward cholesterol: coprecipitation with bile salt and assimilation.Curr . Microbiol. 33, 187-193). However, in the present invention, Bacillus polyfermenticus SCD (KCCM 10104) directly lowers the residual content of cholesterol regardless of the concentration of 'oxgall' 0.0% (v / v) and 0.3% (v / v). It was found to be unaffected by bile acids.
실시예 1: 바실러스 폴리퍼멘티쿠스(Example 1 Bacillus polyfermentus ( Bacillus polyfermenticusBacillus polyfermenticus ) SCD (KCCM 10104)를 포함하는 항콜레스테롤 제제의 제조) Preparation of Anticholesterol Formulations Comprising SCD (KCCM 10104)
바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD 균(KCCM 10104)이 함유된 항콜레스테롤 제제는 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD 균(KCCM 10104)을 통상의 진공동결건조기에 투입하여 동결건조한 다음 캡슐화시켜 제조하였다.Bacillus poly flops mentee kusu (B. polyfermenticus) SCD bacteria wherein the cholesterol formulations (KCCM 10104) containing the Bacillus poly flops mentee kusu (B. polyfermenticus) SCD strain (KCCM 10104) were charged into a conventional freeze-dry vacuum lyophilizer It was prepared by encapsulation.
실시예 2: 바실러스 폴리퍼멘티쿠스( B. polyfermenticus ) SCD (KCCM 10104)를 포함하는 건조효모가공식품의 제조 Example 2: Preparation of dried yeast processed food comprising B. polyfermenticus SCD (KCCM 10104 )
아포형태로 공급된 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104) 14 g을 맥주효모 80 g, 솔비톨 5 g, 해조칼슘 1 g에 첨가하여 건조효모가공식품을 제조하였다.Dried yeast food was prepared by adding 14 g of B. polyfermenticus SCD (KCCM 10104) supplied in apo form to 80 g of beer yeast, 5 g of sorbitol, and 1 g of seaweed calcium.
실시예 3: 바실러스 폴리퍼멘티쿠스( B. polyfermenticus ) SCD (KCCM 10104)를 포함하는 선식의 제조 Example 3: Preparation of a wire comprising a Bacillus poly flops mentee kusu (B. polyfermenticus) SCD (KCCM 10104 )
찹쌀 15 g, 보리쌀 20 g, 멥쌀 15 g, 현미 10 g, 흰콩 5 g, 수수 1 g, 조 1 g, 밀 1 g, 메밀 1 g, 옥수수 5 g, 밤 1 g, 잣 1 g, 호두 1 g, 당근 1 g, 시금치 1 g, 마 1 g, 연자육 1 g, 홍화씨 1 g, 둥글레 1 g, 다시마 2 g, 해태 1 g, 뽕잎 3 g, 누에 3 g, 동충하초 3 g을 함유하는 조성물에 아포형태로 공급된 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104) 5 g을 첨가하여 선식을 제조하였다.15 g of glutinous rice, 20 g of barley rice, 15 g of brown rice, 10 g of brown rice, 5 g of white beans, 1 g of crude, 1 g of wheat, wheat 1 g, buckwheat 1 g, corn 5 g, chestnut 1 g, pine nuts 1 g, walnut 1 g, carrot 1 g, spinach 1 g, hemp 1 g, lotus root 1 g, safflower seed 1 g, roundle 1 g, kelp 2 g, Haitai 1 g, mulberry leaf 3 g, silkworm 3 g, cordyceps 3 g Wire was prepared by adding 5 g of B. polyfermenticus SCD (KCCM 10104) supplied in apo form.
실시예 4: 바실러스 폴리퍼멘티쿠스( B. polyfermenticus ) SCD (KCCM 10104)를 포함하는 가축사료 조성물의 제조 Example 4 Preparation of Livestock Feed Compositions Comprising B. polyfermenticus SCD (KCCM 10104 )
옥수수 45 g, 대두박 30 g, 소맥 15 g, 우지 4 g, 당밀 3 g, 인산칼슘제 2 g, 석회석 0.4 g, 소금 0.2 g, 아포형태로 공급된 바실러스 폴리퍼멘티쿠스(B. polyfermenticus) SCD (KCCM 10104) 5 g을 혼합하여 가축 사료용 조성물을 제조하였다.45 g of corn, 30 g of soybean meal, 15 g of wheat, 4 g of tallow, 3 g of molasses, 2 g of calcium phosphate, 0.4 g of lime, 0.2 g of salt, B. polyfermenticus SCD supplied in apo form 5 g of KCCM 10104) were mixed to prepare a composition for livestock feed.
이상 발명의 상세한 설명에서 확인할 수 있는 바와 같이, 본 발명, 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) SCD (KCCM 10104) 생균을 유효성분으로 함유하는 조성물은 콜레스테롤을 저하시키는 뛰어난 효과가 있으므로 식품, 의약 및 사료산업상 매우 유용한 발명인 것이다.As can be seen from the detailed description of the invention, the composition containing the present invention, Bacillus polyfermenticus SCD (KCCM 10104) live bacteria as an active ingredient has an excellent effect of lowering cholesterol, food, medicine and It is a very useful invention in the feed industry.
도 1은 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) SCD 균주(KCCM 10104)의 배양 시간에 따른 콜레스테롤의 감소경향을 보여주는 그래프이다.1 is a graph showing a trend of decreasing cholesterol according to the culture time of Bacillus polyfermenticus SCD strain (KCCM 10104).
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2002-0073386A KR100518266B1 (en) | 2002-11-25 | 2002-11-25 | Composition comprising Bacillus polyfermenticus SCD (KCCM 10104) for usage as cholesterol-lowering agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2002-0073386A KR100518266B1 (en) | 2002-11-25 | 2002-11-25 | Composition comprising Bacillus polyfermenticus SCD (KCCM 10104) for usage as cholesterol-lowering agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20040045567A KR20040045567A (en) | 2004-06-02 |
| KR100518266B1 true KR100518266B1 (en) | 2005-10-04 |
Family
ID=37341354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2002-0073386A KR100518266B1 (en) | 2002-11-25 | 2002-11-25 | Composition comprising Bacillus polyfermenticus SCD (KCCM 10104) for usage as cholesterol-lowering agent |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100518266B1 (en) |
-
2002
- 2002-11-25 KR KR10-2002-0073386A patent/KR100518266B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040045567A (en) | 2004-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100396769C (en) | Novel probiotics for pet. food applications | |
| JP5872104B2 (en) | New Bacillus subtilis {NOVELBACILLUSSUBTILIS} | |
| Yu et al. | Evaluation of Lactobacillus reuteri Pg4 strain expressing heterologous β-glucanase as a probiotic in poultry diets based on barley | |
| CN100455203C (en) | A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal | |
| KR20000064728A (en) | Promoting microbial metastasis of the gastrointestinal tract | |
| KR102166596B1 (en) | Lactobacillus plantarum JDFM LP11 strain having antimicrobial activity, anti-aging activity and probiotics properties and uses thereof | |
| KR101845709B1 (en) | Lactobacillus plantarum KCC-26 and composition comprising the same | |
| CN111714572B (en) | Lactobacillus plantarum-based probiotic tablet and preparation method thereof | |
| KR101485182B1 (en) | Novel Lactobacillus plantarum from kimchi with inhibiting activities on pathogenic microorganism and use thereof | |
| KR101381547B1 (en) | Novel Leuconostoc mesenteroides from kimchi with inhibiting activities on pathogenic microorganism and use thereof | |
| KR101873898B1 (en) | Novel lactobacillus sp. and feed composition for animal comprising thereof | |
| KR102424594B1 (en) | Lactobacillus fermentum OKBL-L.FE 1 strain having anti-inflammatory activity and antimicrobial activity against pathogenic microorganism and uses thereof | |
| JP3520012B2 (en) | Composition suitable as a nutrient supplement and for treating intestinal disorders and modifying the bacterial flora | |
| KR102327307B1 (en) | Lactobacillus paracasei strain with secretion activation of β-glucuronidase and Fermentative Scutellaria baicalensis and Feed supplement using the same | |
| KR20140087518A (en) | New lactic acid bacteria having GABA-producing activity and composition comprising a cultured broth of the strain | |
| KR100518266B1 (en) | Composition comprising Bacillus polyfermenticus SCD (KCCM 10104) for usage as cholesterol-lowering agent | |
| KR20030075996A (en) | Feed additives using Bacillus subtilis and Saccharomyces cerevisiae, and a method of manufacture thereof | |
| CN112391317B (en) | Probiotic bacterial strain composition for producing cubilose acid and application | |
| KR20050041808A (en) | Leuconostoc citreum km20 that can suppress the growth of pathogenic microorganisms and suppressed tumour growth | |
| Miltko et al. | Can fungal zoospores be the source of energy for the rumen protozoa Eudiplodinium maggii? | |
| KR100518261B1 (en) | Composition comprising Bacillus polyfermenticus SCD (KCCM 10104) for usage as anti-oxidant | |
| KR100442205B1 (en) | Bifidobacterium lactis producing β- glucosidase and method for converting isoflavon into isoflavon aglucon using the same | |
| KR101544180B1 (en) | Novel Lactobacillus plantarum strains having high-productivity of conjugated linoleic acid, and probiotics and conjugated linoleic acid enhanced food prepared by using the strains | |
| KR20020025395A (en) | A New Strain of Bacillus megaterium PS352 Isolated from Soy Sediment and A Probiotic Usage of the Strain | |
| KR20170108214A (en) | Bacillus subtilis hd 9098, probiotics composition including the same and method of manufacturing thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20120914 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20130912 Year of fee payment: 9 |
|
| LAPS | Lapse due to unpaid annual fee |